Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To explore the law of changes in ocular surface inflammation when 0.05% cyclosporine eye drops (II) is used to treat dry eye, 50 cases of mild to moderate dry eyes were included. The expectation is finding out whether cyclosporine has a regulatory effect on conjunctival microvascular parameters and other inflammation indicators after cyclosporine eye drops treat dry eye, and analyze the value of conjunctival microvascular indicators in dry eye immunosuppressive therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• 18-65 years old; meet the 2-3 grade dry eye diagnosis: 1) At least one eye has one or more ocular discomfort symptoms and OSDI score ≥23; 2) At least one eye meets one of the following two: 2 mm/5min≤Schirmer I test (no anesthesia) <10 mm/5min; BUT≤10s. 3) Corneal spotting but no extensive erosion.

Exclusion Criteria:

• Contact lens wearers; allergies to the study drug; active eye infections; history of serious systemic diseases; pregnancy or breastfeeding; receiving or starting other treatments that may interfere with the interpretation of the results; participating any other clinical trials within 3 months; previous eye surgery, including laser treatment and refractive surgery; need or have undergone punctal embolization or nasolacrimal duct obstruction; KCS secondary to the destruction of conjunctival goblet cells (such as vitamin A deficiency) ; Scar formation (such as cicatricial pemphigus, alkali burn, trachoma or radiation).